Action UCB - UCB

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

163,65

Prix Achat

162,50

Prix Vente

162,00

Volume échangé

0,00

0,00 Fourchette du Jour 0,00

125,50 Plage de 52 semaines 198,95

Cap du marché

31,831B

Clôture Veille

163,65

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

334 931

Actions en circulation

194 506 000

Rendement du Dividende

Ratio Cours sur Bénéfices

29,89

Bénéfice par action (BPA)

5,48

Chiffre d'affairess

5,61B

Bénéfice net

1,07B

Secteur

Pharmaceutical Preparations

Industrie

Chemicals & Allied Products

Site Web

www.ucb.com

Siège social

Brussels, Brussels-capital Region, Bel

Fondé

1928

UCB SA est coté dans le secteur Pharmaceutical Preparations de la Euronext avec le ticker UCB. Le dernier cours de clôture d'UCB était de 163,65 €. Au cours de la dernière année, les actions de UCB ont été négociées dans une fourchette de prix de 125,50 € à 198,95 €.

UCB compte actuellement 194 506 000 actions en circulation. La capitalisation boursière d'UCB est de 31,83 € milliard. UCB a un ratio cours/bénéfice (ratio PE) de 29.89.

UCB Convening Notice to the General Meeting of the Shareholders 2025

UCB Convening Notice to the General Meeting of the Shareholders 2025 CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of...

UCB Convocation à l'Assemblée Générale des Actionnaires 2025

UCB Convocation à l'Assemblée Générale des Actionnaires 2025 CONVOCATION A L’ASSEMBLEE GENERALE DES ACTIONNAIRES Le Conseil d’administration...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant...

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	12.15	8.0198019802	151.5	164.05	150.7	200523	159.45526008	DE
4	19.35	13.4095634096	144.3	172.3	143.15	289112	158.35273936	DE
12	-22.65	-12.1578099839	186.3	196.85	129.35	334931	163.44779249	DE
26	-11.35	-6.48571428571	175	198.95	129.35	261085	172.71697829	DE
52	36.2	28.40329541	127.45	198.95	125.5	245884	162.99223655	DE
156	76.03	86.7724263867	87.62	198.95	65.4	265764	107.58251903	DE
260	83.45	104.052369077	80.2	198.95	65.4	279670	101.94246781	DE

UCB - Frequently Asked Questions (FAQ)

What is the current UCB share price?

The current share price of UCB is 163,65 €

How many UCB shares are in issue?

UCB has 194 506 000 shares in issue

What is the market cap of UCB?

The market capitalisation of UCB is EUR 31,83B

What is the 1 year trading range for UCB share price?

UCB has traded in the range of 125,50 € to 198,95 € during the past year

What is the PE ratio of UCB?

The price to earnings ratio of UCB is 29,89

What is the cash to sales ratio of UCB?

The cash to sales ratio of UCB is 5,67

What is the reporting currency for UCB?

UCB reports financial results in EUR

What is the latest annual turnover for UCB?

The latest annual turnover of UCB is EUR 5,61B

What is the latest annual profit for UCB?

The latest annual profit of UCB is EUR 1,07B

What is the registered address of UCB?

The registered address for UCB is 60, ALLEE DE LA RECHERCHE, BRUSSELS, BRUSSELS-CAPITAL REGION, B-1070

What is the UCB website address?

The website address for UCB is www.ucb.com

Which industry sector does UCB operate in?

UCB operates in the CHEMICALS & ALLIED PRODUCTS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
ABCAABC Arbitrage	5,98 € (0,00%)	0
ABAb Science	1,334 € (0,00%)	0
AALBAalberts NV	30,62 € (0,00%)	0
AAAAlan Allman Associates	4,50 € (0,00%)	0
74SW74Software SA	38,50 € (0,00%)	0
ABCAABC Arbitrage	5,98 € (0,00%)	0
ABAb Science	1,334 € (0,00%)	0
AALBAalberts NV	30,62 € (0,00%)	0
AAAAlan Allman Associates	4,50 € (0,00%)	0
74SW74Software SA	38,50 € (0,00%)	0
ABCAABC Arbitrage	5,98 € (0,00%)	0
ABAb Science	1,334 € (0,00%)	0
AALBAalberts NV	30,62 € (0,00%)	0
AAAAlan Allman Associates	4,50 € (0,00%)	0
74SW74Software SA	38,50 € (0,00%)	0

Forums

Afficher les forums

Ucb (Ucb - Bel 20)	5
UCB (Euronext Bruxelles)	7

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

UCB SA (UCB)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de UCB SA

UCB Dernières nouvelles

UCB Convening Notice to the General Meeting of the Shareholders 2025

UCB Convocation à l'Assemblée Générale des Actionnaires 2025

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB Convening Notice to the General Meeting of the Shareholders 2024

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

UCB Convocation à L’ Assemblée Générale des Actionnaires 2023

Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration

UCB Convening Notice to the General Meeting of the Shareholders 2025

UCB Convocation à l'Assemblée Générale des Actionnaires 2025

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

UCB SA (UCB) Cours

UCB SA (UCB)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de UCB SA

UCB Dernières nouvelles

UCB Convening Notice to the General Meeting of the Shareholders 2025

UCB Convocation à l'Assemblée Générale des Actionnaires 2025

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB Convening Notice to the General Meeting of the Shareholders 2024

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

UCB Convocation à L’ Assemblée Générale des Actionnaires 2023

Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration

UCB Convening Notice to the General Meeting of the Shareholders 2025

UCB Convocation à l'Assemblée Générale des Actionnaires 2025

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Connectez-vous

Supprimer les publicités